[HTML][HTML] Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY
J Corren, EG Gil, JM Griffiths, JR Parnes… - Annals of Allergy …, 2021 - Elsevier
Background Patients with severe, uncontrolled asthma experience frequent exacerbations
and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY
study (NCT02054130), tezepelumab reduced exacerbations by up to 71% and improved
lung function, asthma control, and health-related quality of life vs placebo. Objective This
analysis further assessed the impact of tezepelumab on patient-reported outcomes (PROs)
in PATHWAY. Methods Adults with severe, uncontrolled asthma were randomized to …
and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY
study (NCT02054130), tezepelumab reduced exacerbations by up to 71% and improved
lung function, asthma control, and health-related quality of life vs placebo. Objective This
analysis further assessed the impact of tezepelumab on patient-reported outcomes (PROs)
in PATHWAY. Methods Adults with severe, uncontrolled asthma were randomized to …